[Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors].
Authors:
Open Access
- 20 January 2026
- journal article
- review article
- Vol. 29 (1) , 35-46
Abstract
First-line immunotherapy for advanced non-small cell lung cancer (NSCLC) shows significant survival benefits in patients without driver mutations, but the optimal duration of treatment remains controversial. Some studies support limiting immunotherapy to 2 years, arguing that longer treatment does not bring additional survival benefits; while other studies believe that treatment should continue until disease progression to maximize survival benefits. This article systematically reviews the current research progress on the duration of immunotherapy and discusses the potential predictive value of biomarkers such as circulating tumor DNA (ctDNA), the best efficacy response, and programmed cell death ligand 1 (PD-L1) expression levels in individualized treatment decisions. More prospective studies, especially biomarker-driven trials, are still needed to clarify the optimal duration of treatment and establish an individualized treatment strategy based on multidimensional indicators. .Keywords
This publication has 52 references indexed in Scilit:
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLCJournal of Thoracic Oncology, 2021
- Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLCJCO Oncology Practice, 2021
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Journal of Clinical Oncology, 2021
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2021
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153Journal of Clinical Oncology, 2020
- Duration of nivolumab for pretreated, advanced non–small‐cell lung cancerCancer Medicine, 2020
- Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case ReportsInternational Journal of Molecular Sciences, 2019
- Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyThe Lancet Respiratory Medicine, 2019
- Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK studyEuropean Journal of Cancer, 2019
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017